Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
Dec 11, 2023 · GSK plc (LSE/NYSE: GSK) today announced t he European Commission (EC) has granted marketing authorisation for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent ...
US FDA expands Jemperli (dostarlimab) plus chemotherapy approval ... - GSK
Aug 1, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer.
Jemperli (dostarlimab) trial continues to show unprecedented ... - GSK
Jun 3, 2024 · GSK is advancing studies evaluating dostarlimab in patients with advanced/metastatic stages of dMMR/MSI-H colorectal cancer through its AZUR clinical trial programme.
About JEMPERLI (dostarlimab-gxly) - GSK
Aug 17, 2021 · GlaxoSmithKline (GSK) plc today announced the US Food and Drug Administration (FDA) approved a new indication for JEMPERLI (dostarlimab-gxly), a programmed cell death receptor-1 (PD-1) blocking antibody, for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid …
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial …
Jan 21, 2025 · The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC).
GSK bags sought-after Jemperli okay in endometrial cancer
5 days ago · The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for...
ESMO: Jemperli appears to show survival edge over Keytruda
Oct 20, 2023 · Compared with Merck’s market-leading Keytruda, GSK’s Jemperli demonstrated a 25% lower risk of death in patients with newly diagnosed nonsquamous non-small cell lung cancer (NSCLC), according to...
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy …
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer.